ImageneBio (IMA) Non-Current Debt (2023 - 2024)
ImageneBio's (IMA) quarterly Non-Current Debt came in at $1.1 million in Q4 2024, up 11.68% year-on-year from $950000.0 in Q1 2024, and up 11.68% quarter-over-quarter from $950000.0 in Q4 2023.
ImageneBio (IMA) Non-Current Debt (2023 - 2024) Analysis & Trends
ImageneBio has disclosed Non-Current Debt across 2 years of filings, most recently posting $1.1 million for Q4 2024.
- Non-Current Debt for Q4 2024 came in at $1.1 million, up 11.68% year-over-year; the trailing twelve-month figure through Dec 2024 was $1.1 million (up 11.68% YoY), and the FY2024 annual result was $1.1 million, up 11.68% from the prior year.
- Non-Current Debt came in at $1.1 million for Q4 2024 at ImageneBio, up from $950000.0 in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $1.1 million in Q4 2024 to a low of $852000.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 319.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | ImageneBio | 3.18 Mn | 3.18 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 1.06 Mn |
| Dec 31, 2024 | 1.06 Mn |
| Dec 31, 2023 | 950,000.00 |
| Dec 31, 2023 | 950,000.00 |
| Sep 30, 2023 | 852,000.00 |
| Sep 30, 2023 | 852,000.00 |